

ABL Europe unites with Hookipa Biotech

01 March 2018 | News

Hookipa will utilize the recently expanded GMP viral vector facilities



Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology.

ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.

Under the agreement, ABL will perform process transfer, scale-up and GMP manufacturing of attenuated replicating viral vectors based on Hookipa's proprietary arenavirus heterologous TheraT® platform.

Under the manufacturing collaboration, Hookipa will utilize the recently expanded GMP viral vector facilities and capacities of ABL Europe's new state-of-the-art single use suite able to support both adherent and suspension cell culture capabilities at a 200 L and 500 L SUB scale.

In addition to the supply of drug substance, ABL will manufacture aseptic drug product for Hookipa in-house at the Strasbourg facility, able to accommodate batch sizes in the region of 10,000 vials.